EFFICIENCY AND PERFORMANCE OF THE USE OF RECOMBINANT INTERFERON GAMMA IN COMPLEX THERAPY OF INFLUENZA A(H1N1)PDM09 PATIENTS
T. V Sologub , A. S Midikari , V. N Agafonov , A. A Suzdalcev , V. V Tsvetkov
Epidemiology and Infectious Diseases ›› 2017, Vol. 22 ›› Issue (2) : 58 -63.
EFFICIENCY AND PERFORMANCE OF THE USE OF RECOMBINANT INTERFERON GAMMA IN COMPLEX THERAPY OF INFLUENZA A(H1N1)PDM09 PATIENTS
In the period of the epidemic rise in the incidence rate of influenza in 2015-2016 on the basis of infectious hospitals in Simferopol, Arkhangelsk and Samara, there performed a multicenter to evaluate the effectiveness and economic feasibility of two alternative treatment regimens for influenza A (H1N1) pdm09 patients. The study included 88 patients with a laboratory-confirmed diagnosis of influenza A (H1N1)pdm09. Patients of the main group (n = 46) received complex therapy with the use of antiviral (oseltamivir) and immunomodulating (interferon gamma) agents. Patients of the control group (n = 40) received only antiviral therapy (oseltamivir). To assess the effectiveness and economic feasibility of the two different treatment regimens, the outcome of the disease was analyzed: the discharge the hospital up to the 10th day of the illness and no symptoms of the disease by the 3-6th day of treatment. The supplementation of recombinant interferon gamma in the treatment regimen of influenza A (H1N1) pdm09 patients was found to promote the faster release of catarrhal and respiratory symptoms of the disease: the absence of dry cough by the 3-6th day of treatment (RR = 1.43, 95% CI: 0.86 - 2.38), rhinitis (RR 1.21, 95% CI 1.05-1.40) and dyspnea (RR= 1.28, 95% CI: 1.06-1.54). In addition, the supplementation of recombinant interferon gamma in the treatment regimen of patients with influenza A (H1N1)pdm09 promoted a significant shortening of time of the recovery and discharge from the hospital (RR =1.39, 95% CI: 0.97 - 2.00). Clinical and economic analysis of the use of two alternative treatment regimens has shown the supplementation of recombinant interferon gamma in the therapy of influenza A (H1N1) pdm09 patients to be economically favorable
influenza / influenza A (H1N1) pdm09 / influenza treatment / antiviral flu therapy / immunomodulatory therapy for influenza / interferon gamma / Tamiflu / Ingaron
| [1] |
Subramaniam P.S., Torres B.A., Johnson H.M. So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors. Cytokine. 2001; 15: 175-87. |
| [2] |
Frucht D.M., Fukao T., Boqdan C., Schindler H., O’shea J.J. et al. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 2001; 22: 556-60. |
| [3] |
Adams D.O. Molecular interactions in macrophage activation. Trends Immunol. 1989; 10: 33-5. |
| [4] |
Munder M., Mallo M., Eichmann K., Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J. Exp. Med. 1998; 187: 2103-8. |
| [5] |
Sen G.C. Viruses and interferons. Annu. Rev. Microbiol. 2001; 55: 255-81. |
| [6] |
Young H.A., Hardy K.J. Role of interferon-gamma in immune cell regulation. J. Leukoc. Biol. 1995; 58: 373-81. |
| [7] |
Bach E.A., Aguet M., Schreiber R.D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 1997; 15: 563-91. |
| [8] |
Bot A., Bot S., Bona C.A. Protective role of gamma interferon during the recall response to influenza virus. J. Virol. 1998; 72 (8): 6637-45. |
Eco-vector
/
| 〈 |
|
〉 |
PDF
